Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study - Archive ouverte HAL Access content directly
Journal Articles Alzheimer's Research and Therapy Year : 2016

Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study

, (1) , , , , , , , , , , , , , , , ,
Claire Paquet
  • Function : Author
Eloi Magnin
David Wallon
  • Function : Author
Anne-Cécile Troussière
  • Function : Author
Julien Dumurgier
Alain Jager
  • Function : Author
Frank Bellivier
Elodie Bouaziz-Amar
  • Function : Author
Frédéric Blanc
Emilie Beaufils
  • Function : Author
Carole Miguet-Alfonsi
  • Function : Author
Muriel Quillard
  • Function : Author
Susanna Schraen
  • Function : Author
Florence Pasquier
  • Function : Author
Didier Hannequin
  • Function : Author
Philippe Robert
Jacques Hugon
  • Function : Author
François Mouton-Liger
  • Function : Author


Abstract Background Affective and psychotic disorders are mental or behavioural patterns resulting in an inability to cope with life’s ordinary demands and routines. These conditions can be a prodromal event of Alzheimer’s disease (AD). The prevalence of underlying AD lesions in psychiatric diseases is unknown, and it would be helpful to determine them in patients. AD cerebrospinal fluid (CSF) biomarkers (amyloid β, tau and phosphorylated tau) have high diagnostic accuracy, both for AD with dementia and to predict incipient AD (mild cognitive impairment due to AD), and they are sometimes used to discriminate psychiatric diseases from AD. Our objective in the present study was to evaluate the clinical utility of CSF biomarkers in a group of patients with psychiatric disease as the main diagnosis. Methods In a multicentre prospective study, clinicians filled out an anonymous questionnaire about all of their patients who had undergone CSF biomarker evaluation. Before and after CSF biomarker results were obtained, clinicians provided a diagnosis with their level of confidence and information about the treatment. We included patients with a psychiatric disorder as the initial diagnosis. In a second part of the study conducted retrospectively in a followed subgroup, clinicians detailed the psychiatric history and we classified patients into three categories: (1) psychiatric symptoms associated with AD, (2) dual diagnosis and (3) cognitive decline not linked to a neurodegenerative disorder. Results Of 957 patients, 69 had an initial diagnosis of a psychiatric disorder. Among these 69 patients, 14 (20.2 %) had a CSF AD profile, 5 (7.2 %) presented with an intermediate CSF profile and 50 (72.4 %) had a non-AD CSF profile. Ultimately, 13 (18.8 %) patients were diagnosed with AD. We show that in the AD group psychiatric symptoms occurred later and the delay between the first psychiatric symptoms and the cognitive decline was shorter. Conclusions This study revealed that about 20 % of patients with a primary psychiatric disorder diagnosis before undergoing a CSF exploration for cognitive disorder displayed a CSF biomarker AD profile. In memory clinics, it seems important to consider AD as a possible diagnosis before finalizing a diagnosis of a psychiatric disorder.

Dates and versions

hal-03630210 , version 1 (04-04-2022)



Claire Paquet, Eloi Magnin, David Wallon, Anne-Cécile Troussière, Julien Dumurgier, et al.. Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. Alzheimer's Research and Therapy, 2016, 8 (1), pp.27. ⟨10.1186/s13195-016-0192-z⟩. ⟨hal-03630210⟩


12 View
0 Download



Gmail Facebook Twitter LinkedIn More